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Abstract 
Sequential use of endocrine therapies remains the cornerstone of treatment for hormone 
receptor-positive advanced breast cancer, prior to use of cytotoxic chemotherapy for 
unresponsive disease. Fulvestrant is an estrogen receptor (ER) antagonist approved for 
treatment of postmenopausal women with ER+ advanced breast cancer following failure of 
prior antiestrogen therapy. Initially approved at a monthly dose of 250 mg, the recommended 
fulvestrant dose was revised to 500 mg (500 mg/month plus 500 mg on Day 14 of Month 1) 
following demonstration of improved progression-free survival versus fulvestrant 250 mg. 
We have reviewed the dose-dependent effects of fulvestrant, both from a retrospective 
combined analysis of dose-dependent reduction of tumor biomarkers in the pre-surgical 
setting (three previously reported studies: Study 18, NEWEST [Neoadjuvant Endocrine 
Therapy for Women with Estrogen-Sensitive Tumors] and Trial 57), and from a review of 
clinical studies for advanced breast cancer in postmenopausal women. Analysis of pre-
surgical data revealed a consistent dose-dependent effect for fulvestrant on tumor biomarkers, 
with increasing fulvestrant dose resulting in greater reductions in ER, progesterone receptor 
and Ki67 labeling index. The dose-dependent biological effect corresponds with the dose-
dependent clinical efficacy observed in the treatment of advanced breast cancer following 
failure of prior antiestrogen therapy. Although it remains to be determined in a Phase III trial, 
cross-trial comparisons suggest a dose-dependent relationship for fulvestrant as first-line 
treatment for advanced breast cancer. Overall, biological and clinical data demonstrate a 
strong dose-dependent relationship for fulvestrant, supporting the efficacy benefit seen with 
fulvestrant 500 mg over the 250 mg dose. 
Key words [not in the article or journal title]: advanced breast cancer; endocrine therapy; 
estrogen receptor; postmenopausal; tumor biomarkers 
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Introduction 
Endocrine therapies provide effective and well-tolerated treatments for postmenopausal 
women with hormone receptor-positive breast cancer (estrogen receptor-positive [ER+] 
and/or progesterone receptor-positive [PgR+]), both in the adjuvant setting
1
 and for the 
treatment of advanced disease.
2
 
Aromatase inhibitors (AIs), which block production of estrogen through their interaction with 
the estrogen-producing enzyme aromatase, have demonstrated increased efficacy compared 
with the ER antagonist tamoxifen in postmenopausal women as first-line endocrine treatment 
for ER+ advanced breast cancer,
3-6
 and as adjuvant therapy for postmenopausal women with 
early breast cancer.
7-9
 As such, AIs are now considered the standard of care as adjuvant 
endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer.  
Fulvestrant, a 17β-estradiol analog, is an ER antagonist that competes with endogenous 
estrogen for binding to the ER.
10
 However, unlike tamoxifen, which exhibits partial estrogen 
agonist activity, fulvestrant has no recognized estrogenic effect. It is thought that this is due 
to the fact that upon binding to the ER, fulvestrant induces a conformational change, leading 
to degradation of the ER and complete inhibition of ER signaling in animal models.
11
 
Unfortunately, resistance to endocrine therapy will eventually develop. While optimal 
sequencing of appropriate hormone therapies is the ideal approach, very few randomized 
controlled trials have directly compared the effects of changing the order in which two 
different agents are given.
2
 Furthermore, the paucity of data led the authors of a recent review 
to conclude that no definitive recommendations could be made regarding the sequencing of 
endocrine therapies in patients with advanced breast cancer, and that patients should receive 
the most efficacious treatment in that setting, whilst also considering specific side effect 
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issues for that patient.
2
 Early pre-clinical data demonstrated a lack of cross-reactivity between 
fulvestrant and tamoxifen with fulvestrant inhibiting growth of tamoxifen-resistant tumors.
12
 
Similarly in the clinical setting, many postmenopausal women with advanced breast cancer 
that responded to first-line fulvestrant remained responsive to further endocrine treatment.
13,14
 
Furthermore, tumors that have responded to prior treatment with an antiestrogen
15,16
 or an 
AI
17,18
 may retain sensitivity to subsequent treatment with fulvestrant. 
Pre-surgical studies provide the opportunity to perform a detailed analysis and comparison of 
biomarker expression and biomarker response to various experimental drug treatments. As an 
example, the selective estrogen receptor modulator tamoxifen was reported to increase PgR 
levels as a result of its partial estrogen agonist activity.
19
 However, down regulation of ER 
with fulvestrant leads to reduction in PgR protein levels through disruption of ER-dependent 
transcription of the PgR gene, as shown in a randomized comparison with tamoxifen, 
highlighting the distinct mechanisms of action of these two agents.
20
 Reduction in Ki67 
expression, a nuclear antigen and marker of cell proliferation, is reported to correlate with 
treatment response to endocrine therapy in ER+ breast cancer,
21
 and Ki67 in short-term 
neoadjuvant studies has been shown to predict outcome in long-term adjuvant trials.
22
 
Clinical efficacy of fulvestrant was demonstrated in postmenopausal women with advanced 
breast cancer that had progressed or recurred on prior antiestrogen therapy
16,23,24
 and was 
originally approved at a monthly dose of 250 mg. However, a dose-dependent effect was 
subsequently shown, with improved progression-free survival (PFS) for fulvestrant 500 mg 
(500 mg/month intramuscular [i.m.] injection plus 500 mg on Day 14 of Month 1) versus the 
250 mg dose. This led to approval of the 500 mg dose for the treatment of postmenopausal 
women with ER+ advanced breast cancer following failure of prior antiestrogen therapy.
25
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This review investigates the dose-dependent effects of fulvestrant more broadly, both in 
terms of the reduction of tumor biomarkers in the pre-surgical setting, and in clinical efficacy 
for the treatment of breast cancer. 
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Biological rationale for a dose-response relationship for fulvestrant 
Dose-dependent reduction of tumor  biomarkers following fulvestrant treatment was first 
demonstrated in a short-term pre-surgical study in postmenopausal women with primary 
breast cancer.
26
 Following daily injections of a short-acting formulation of fulvestrant, 
reductions in ER expression and Ki67 labeling index were greater in patients with ER+ breast 
cancer who received a fulvestrant 18 mg daily injection compared with those who received a 
fulvestrant 6 mg daily injection.  
We now extend the study of dose dependency by presenting a retrospective analysis of tumor 
biomarker data, extracted from three previously reported pre-surgical studies over a 
fulvestrant dose range of 50–500 mg, administered using the commercially available long-
acting formulation. Data from Study 18,
20
 NEWEST (Neoadjuvant Endocrine Therapy for 
Women with Estrogen-Sensitive Tumors),
27
 and Trial 57
28
 were combined in this analysis. 
Study designs 
Study 18 
Study 18 was a randomized, multicenter, partially blinded study that compared placebo, 
tamoxifen, fulvestrant 50 mg, fulvestrant 125 mg, and fulvestrant 250 mg prior to surgery in 
postmenopausal women with previously untreated primary breast cancer.
20
 Patients received 
a single i.m. dose of fulvestrant 50 mg, 125 mg, 250 mg, or tamoxifen 20 mg daily, or 
tamoxifen placebo daily for 14–21 days prior to surgery. Only data from patients whose 
tumors were ER+ or PgR+ have been included in the current analysis. Where patients had 
more than one tumor, baseline data from only the primary tumor were included. 
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NEWEST 
NEWEST (ClinicalTrials.gov identifier NCT0093002) was a randomized, multicenter, open-
label, Phase II study comparing fulvestrant 500 mg (500 mg/month plus 500 mg on Day 14 of 
Month 1) with fulvestrant 250 mg/month for 16 weeks prior to surgery in postmenopausal 
women with ER+ locally advanced breast cancer.
27
 Tumor biomarker levels at Week 4 have 
been used in the present analysis for the closest consistency with data from Study 18 and 
Trial 57. 
Trial 57 
Trial 57 (ClinicalTrials.gov identifier NCT00259090) was a randomized, multicenter, double-
blind, Phase II trial comparing fulvestrant 500 mg (single i.m. dose) plus anastrozole (1 mg 
orally once daily for 14–21 days), or fulvestrant 500 mg plus anastrozole placebo, or 
anastrozole plus fulvestrant placebo prior to surgery in postmenopausal women with ER+ 
primary breast cancer.
28
 Prior to protocol amendment, Trial 57 included a treatment phase in 
which patients were randomized to receive fulvestrant 250 mg plus anastrozole (n=6), 
fulvestrant 250 mg plus anastrozole placebo (n=6), or anastrozole 1 mg plus fulvestrant 
placebo (n=6). Although patient numbers are small and should therefore be interpreted with 
caution, data for this initial treatment phase have been included for completeness in this 
analysis.  
Tumor biomarker expression and statistical analyses 
ER, PgR and Ki67 expression were determined in each study by immunochemistry on 
sections of formalin-fixed, paraffin-embedded tissue. Study 18 used the following antibodies: 
ER, H222 (Abbott); PgR, KD68 (Abbott); Ki67, MIB-1 (Coulter Electronics). In NEWEST, 
the antibodies used were: ER, 1D5 (Dako Ltd); PgR, 636 (Dako Ltd); Ki67, MIB-1 (Coulter 
Electronics). The antibodies used in Trial 57 were as follows: ER, 6F11 (Novocastra); PgR, 
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636 (Dako Ltd); Ki67, Clone MIB-1 (Dako Ltd). Antigen retrieval methods and secondary 
detection methods varied between the studies and have been described previously.
20,27,28
 ER, 
PgR and Ki67 expression levels at pre- and post-treatment (14–21 days post-treatment in 
Study 18 and Trial 57 and at Week 4 in NEWEST) were determined by manual counting 
under light microscopy. ER and PgR expression were determined as the H-score, calculated 
as (0.5×% +/-) + (1×% +) + (2×% ++) + (3×% +++), where % +/-, % +, % ++, and % +++ 
represent the overall percentage positivity of very weak, weak, moderate, and strong staining, 
respectively. Ki67 expression was determined as the labeling index, derived from the number 
of positively stained epithelial cells, expressed as a percentage of the total number of cells 
counted.  
Tumor biomarker expression data were analyzed by study using an analysis of covariance 
(ANCOVA) model (log-transformed ratio of post- to pre-treatment) with the log-transformed 
baseline value and treatment included as factors.  The least squares mean and confidence 
interval (CI) values were back-transformed to the original scale. To assess the impact of 
fulvestrant dose while allowing for between-study variability, a second ANCOVA model was 
produced including log-transformed baseline, dose (as a continuous variable), and study as 
factors. The first ANCOVA included all treatment groups within each trial; the second 
ANCOVA included only placebo and the fulvestrant 50 mg, 125 mg, 250 mg, and 500 mg 
treatment groups. In order for the placebo data to be log-transformed, a dose of 0.5 mg rather 
than 0 mg was used for the purpose of this analysis. 
ER H-score 
In Study 18, NEWEST, and Trial 57, a dose-dependent effect was seen over the dose ranges 
investigated for reduction in ER expression. In each study, the greatest reduction in ER 
expression was seen with the highest fulvestrant dose. In Study 18, greater reduction in ER 
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was observed for fulvestrant 250 mg versus tamoxifen, and in Trial 57, greater reduction in 
ER expression was observed for fulvestrant 500 mg versus anastrozole. In Trial 57, no 
additional reduction in ER expression was observed for fulvestrant 500 mg plus anastrozole 
compared with fulvestrant 500 mg alone (Table 1; Figure 1). 
PgR H-score 
A consistent dose-dependent effect of fulvestrant was also observed in Study 18, NEWEST, 
and Trial 57 for reduction in PgR expression. The greatest reduction in PgR expression was 
seen with the highest fulvestrant dose within each study. An increase in PgR expression was 
seen in the tamoxifen treatment group in Study 18. In Trial 57, no additional reduction in PgR 
expression was observed for the combination of fulvestrant 500 mg plus anastrozole 
compared with either fulvestrant 500 mg alone or anastrozole alone. Similar reductions in 
PgR expression were observed for fulvestrant 500 mg alone and anastrozole alone (Table 2; 
Figure 2). 
Ki67 labeling index 
Ki67 labeling index was reduced following treatment in each fulvestrant treatment group in 
each study. In Study 18 and NEWEST, the greatest reduction in Ki67 labeling index was seen 
with the highest fulvestrant dose. In Trial 57, which also included the small initial cohort of 
patients treated with fulvestrant 250 mg (n=6), there were no meaningful differences in Ki67 
labeling index reduction between the fulvestrant treatment groups (Table 3; Figure 3).  
Overall results from the ANCOVA model show a consistent dose-dependent effect for 
fulvestrant over the dose ranges analyzed for ER and PgR H-score and Ki67 labeling index. 
Results for the second ANCOVA, which adjusted for between-study variability, show that 
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increasing fulvestrant dose results in greater reduction in ER and PgR H-score and Ki67 
labeling index (p<0.0001 for the dose–response relationship for each biomarker).  
13 
 
Clinical evidence of a dose–response relationship for fulvestrant 
Fulvestrant dose–response in second-line therapy for advanced breast cancer 
The clinical efficacy of fulvestrant at a dose of 250 mg/month was established in the 
registration trials 0020 and 0021, which compared fulvestrant 250 mg with anastrozole for 
the treatment of postmenopausal women with advanced breast cancer that had progressed or 
recurred on prior antiestrogen therapy.
23,24
 In a combined analysis of data from both studies 
(fulvestrant, n=428; anastrozole, n=423), fulvestrant 250 mg was shown to be at least as 
effective as anastrozole with respect to time to progression (TTP). Median TTP was 5.5 
months for fulvestrant 250 mg compared with 4.1 months for anastrozole (hazard ratio [HR] 
0.95; 95.14% CI 0.82, 1.10; p=0.48).
16
 This led to the approval of fulvestrant 250 mg for the 
treatment of postmenopausal women with advanced breast cancer that had progressed or 
recurred on prior antiestrogen therapy. However, evidence of dose-dependent clinical 
efficacy with fulvestrant had already been suggested in these studies, as an initial 125 mg 
dose was dropped following a planned interim assessment that found no evidence for clinical 
efficacy at the fulvestrant 125 mg dose. Given the favorable tolerability profile of fulvestrant 
250 mg, alternative dosing regimens were investigated.  
The Phase III CONFIRM (COmparisoN of Faslodex In Recurrent or Metastatic breast 
cancer) trial was designed to compare fulvestrant 500 mg with fulvestrant 250 mg in patients 
with hormone receptor-positive, pre-treated, advanced breast cancer. Fulvestrant 500 mg 
significantly prolonged PFS versus fulvestrant 250 mg. Median PFS was 6.5 months in the 
fulvestrant 500 mg group compared with 5.5 months in the fulvestrant 250 mg group (HR 
0.80; 95% CI 0.68, 0.94; p=0.006), demonstrating a clear dose-dependent relationship for 
fulvestrant in this setting (Table 4).
25
 Importantly, the dose-dependent clinical efficacy seen 
in CONFIRM was not associated with a dose-dependent increase in toxicity, with no 
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substantial differences between the treatment groups in terms of incidence and severity of 
adverse events. This increase in therapeutic index led to fulvestrant 500 mg becoming the 
recommended dose. This benefit was further confirmed in a follow-up analysis, performed 
when approximately 75% of patients had died. Median overall survival was 26.4 months for 
fulvestrant 500 mg compared with 22.3 months for fulvestrant 250 mg, indicating a clinically 
relevant difference in overall survival between the treatment groups (HR 0.81; 95% CI 0.69, 
0.96; nominal p=0.016).
29
 
Fulvestrant dose–response in first-line therapy for advanced breast cancer 
Cross-trial comparisons also suggest a dose–response relationship for fulvestrant as first-line 
therapy for advanced breast cancer. In Trial 25, fulvestrant 250 mg failed to demonstrate non-
inferiority compared with tamoxifen, the standard of care at the time of the trial, in 
postmenopausal women with advanced breast cancer previously untreated with endocrine 
therapy for advanced disease.
30
 As anastrozole was previously shown to demonstrate 
improvements in efficacy over tamoxifen,
3
 this was considered a surprising outcome for 
fulvestrant 250 mg. However, with the almost immediate separation of the TTP curves in this 
trial, it was hypothesized that the 3–6 months to steady state for the fulvestrant 250 mg 
regimen could have led to the under-performance of this treatment group.  
In the Phase II FIRST study (Fulvestrant fIRst-line Study comparing endocrine Treatments), 
fulvestrant 500 mg was compared with anastrozole in postmenopausal women with advanced 
breast cancer who had not received endocrine therapy for advanced disease. The fulvestrant 
500 mg dose regimen, which includes a 500 mg dose at Day 14, was shown to be at least as 
effective as anastrozole in terms of the primary endpoint of clinical benefit rate (fulvestrant, 
72.5%; anastrozole, 67.0%) and the secondary endpoint of TTP was significantly longer for 
fulvestrant 500 mg compared with anastrozole.
31
 Safety data indicated that fulvestrant 500 
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mg has a similar tolerability profile compared with anastrozole 1mg, and is well tolerated as 
first-line therapy for advanced breast cancer. In a follow-up analysis, which was performed 
when disease had progressed in approximately 75% of patients, median TTP was 
23.4 months for fulvestrant 500 mg compared with 13.1 months for anastrozole (hazard ratio 
0.66; 95% CI 0.47, 0.92; p=0.01).
14
 This was the first trial to indicate that an alternative 
endocrine therapy may be more effective than an AI in the first-line setting for advanced 
breast cancer, and indirectly suggests a dose–response relationship for fulvestrant 500 mg 
over fulvestrant 250 mg as first-line therapy for advanced breast cancer. Given that 
fulvestrant 250 mg demonstrated non-inferiority to anastrozole (in the second-line setting of 
the registration trials 0020 and 0021
16,23,24
), the significantly longer TTP with fulvestrant 500 
mg versus anastrozole in the first-line setting was also indirect evidence of a dose–response 
relationship for fulvestrant. 
Fulvestrant dose–response in the neoadjuvant setting 
NEWEST was the first study to compare the biological and clinical activity of the fulvestrant 
500 mg dose regimen versus fulvestrant 250 mg. Whilst the primary endpoint of NEWEST 
was biological (change in Ki67 labeling index from baseline to Week 4), the clinical data 
appeared to correspond with the dose-dependent reduction in tumor biomarkers seen at Week 
4. The tumor response rate at Week 4 was 17.4% for the fulvestrant 500 mg group compared 
with 11.8% in the fulvestrant 250 mg group (odds ratio [OR] 1.68; 95% CI 0.77, 3.70; 
p=0.19). At Week 16, tumor response was 22.9% in the fulvestrant 500 mg group compared 
with 20.6% in the fulvestrant 250 mg group (OR 1.30; 95% CI 0.64, 2.64; p=0.47). 
27
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Fulvestrant in combination therapy 
Together with its distinct mechanism of action and reduced risk of cross-resistance with other 
endocrine treatments, the observation of incomplete ER reduction with fulvestrant 250 mg, 
both in the short,
20
 medium, and long term
32,33
 led to combination therapies being developed, 
aiming to further reduce ER activity and improve efficacy. The FACT (Fulvestrant and 
Anastrozole Combination Therapy) study compared the efficacy of a combination of 
anastrozole plus the fulvestrant 250 mg loading dose (LD) regimen (fulvestrant 250 mg + 
LD: 500 mg Day 0, 250 mg Days 14 and 28, 250 mg/month thereafter) versus anastrozole 
alone as therapy for postmenopausal women at first relapse after primary treatment for 
localized hormone receptor-positive breast cancer.
34
 Over 60% of the participants had 
received a prior endocrine therapy in the adjuvant setting. For the primary endpoint, median 
TTP was 10.8 months in the fulvestrant 250 mg + LD plus anastrozole combination 
compared with 10.2 months in the anastrozole alone treatment group (HR 0.99; 95% CI 0.81, 
1.20; p=0.91).
34
 The overall incidence of AEs was similar between the two treatment groups. 
Secondary endpoints including objective response rate, clinical benefit rate and overall 
survival were also similar between the two study arms, indicating no benefit for the 
anastrozole plus fulvestrant combination over anastrozole alone.  
The randomized Phase III SWOG S0226 trial also compared the combination of anastrozole 
plus fulvestrant 250 mg + LD with anastrozole alone as first-line therapy for postmenopausal 
women with metastatic breast cancer.
35
 The primary endpoint of PFS was significant in favor 
of the combination group: 15.0 months compared with 13.5 months in the anastrozole alone 
group (HR 0.80; 95% CI 0.68, 0.94; p=0.007), and no safety concerns were raised with the 
fulvestrant plus anastrozole combination. In a retrospective analysis of those patients naïve to 
prior tamoxifen therapy (414/694 patients: 59.7%), median PFS was 17.0 months in the 
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combination group compared with 12.6 months in the anastrozole alone group (HR 0.74; 
95% CI 0.59, 0.92; p=0.006). In those patients who had received previous treatment with 
tamoxifen (280/694 patients: 40.3%), median PFS was 13.5 months in the combination group 
compared with 14.1 months in the anastrozole alone group (HR 0.89; 95% CI 0.69, 1.15; 
p=0.37).
35
 In total, 166 out of 514 patients (32.3%) had received no prior adjuvant endocrine 
therapy in the FACT trial, whereas 414 out of 694 patients (59.7%) were naïve to prior 
tamoxifen in SWOG S0226. In both trials, less than 2% of patients had received adjuvant 
therapy with an AI. As the percentage of patients who were naïve to prior adjuvant endocrine 
treatment was lower in the FACT trial, and any potential differences in clinical effectiveness 
may be more pronounced when comparing endocrine agents in hormone-naïve patients, this 
could provide one potential explanation for the differences in efficacy between the FACT and 
SWOG S0226 trials. Furthermore, initial data from the SoFEA trial failed to demonstrate 
improved efficacy for the combination of fulvestrant with an AI over a monotherapy 
treatment in the second-line setting. Similar PFS was reported for fulvestrant 250 mg + LD in 
combination with anastrozole compared with fulvestrant alone in postmenopausal patients 
with advanced breast cancer following progression on non-steroidal AIs.
36
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Discussion 
Our analysis of fulvestrant in three pre-surgical studies demonstrates a strong dose-dependent 
biological effect in the reduction of tumor biomarkers. Across each dataset analyzed, 
increasing fulvestrant dose leads to increased reduction in ER, PgR and Ki67, and this dose-
dependent reduction in tumor biomarkers corresponds to the dose-dependent clinical efficacy 
seen in postmenopausal women with advanced breast cancer in the second-line setting of 
trials 0020 and 0021 (fulvestrant 250 mg vs 125 mg) and CONFIRM (fulvestrant 500 mg vs 
250 mg). In the first-line setting, increased efficacy of fulvestrant 500 mg (vs anastrozole in 
FIRST) versus 250 mg (versus tamoxifen in Trial 25) has also been implied through indirect, 
cross-trial comparisons. Further cross-trial comparisons show that in the registration trials 
0020 and 0021 (in the second-line setting), fulvestrant 250 mg was non-inferior to 
anastrozole, but in the Phase II FIRST trial (fulvestrant 500 mg vs anastrozole in the first-line 
setting), fulvestrant demonstrated significantly longer TTP. The ongoing Phase III FALCON 
(Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer) 
trial (ClinicalTrials.gov identifier: NCT01602380) will provide the additional evidence 
required, for registration purposes, to determine if fulvestrant 500 mg is a better option than 
anastrozole 1 mg as first-line hormonal therapy for postmenopausal women with locally 
advanced or metastatic breast cancer.  
Other than the SWOG S0226 trial, clinical data do not support the combination of an 
antiestrogen with an AI. While it is possible that the fulvestrant 250 mg loading dose used in 
the FACT and SoFEA trials was sub-optimal and that efficacy might have been improved 
with the 500 mg dose, biological data using fulvestrant 500 mg do not suggest there will be 
an additional benefit by adding an AI to fulvestrant 500 mg.
28
 Unfortunately, the SWOG 
S0226 trial did not have a third treatment arm of fulvestrant 250 mg alone, which would have 
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clarified whether the longer TTP seen with the combination would have been achieved with 
fulvestrant alone in the first-line setting. The data from SWOG S0226 should therefore be 
used to generate hypotheses for studies to understand if and why this finding is real.  
The dose-dependent effect on tumor biomarkers seen here in postmenopausal women may 
also be evident in pre-menopausal women receiving fulvestrant in clinical studies. In contrast 
to postmenopausal women, where fulvestrant 250 mg was shown to be effective in reducing 
ER, PgR, and Ki67, a previous study demonstrated that fulvestrant 250 mg did not effectively 
reduce expression of ER, PgR, or Ki67 in pre-menopausal women, who are known to have 
much higher levels of circulating estrogen which would be expected to compete with 
fulvestrant for binding to ER.
37
 A single fulvestrant dose of 750 mg was subsequently shown 
to reduce ER levels in pre-menopausal women with primary breast cancer, to an extent 
similar to that seen with fulvestrant 250 mg in postmenopausal women, suggesting a dose–
response relationship for fulvestrant in these patients.
38
 
The dose-dependent biomarker data presented here also correspond to the previously-reported 
pharmacokinetic profile of fulvestrant. Following a single injection of either fulvestrant 
50 mg, 125 mg, or 250 mg, dose-linear pharmacokinetics were observed.
39
 In the NEWEST 
study, plasma levels and exposure with fulvestrant 500 mg were approximately double that of 
fulvestrant 250 mg at Week 16, demonstrating a linear dose-dependent effect.
40
  
In addition to increasing the monthly fulvestrant dose in postmenopausal women, early 
pharmacokinetic and clinical data suggested that alternative regimens could be utilized to 
increase clinical efficacy. At the fulvestrant 250 mg/month dose, it takes 3–6 months to 
achieve steady-state plasma levels.
41
 Therefore, alternative dose regimens were explored 
incorporating a loading dose component with the aim of reducing the time to reach steady-
state and achieving earlier down regulation of ER. In EFECT (Evaluation of Faslodex versus 
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Exemestane Clinical Trial), fulvestrant 250 mg + LD was employed (fulvestrant 250 mg + 
LD: 500 mg Day 0, 250 mg Days 14 and 28, 250 mg/month thereafter) and the time required 
for fulvestrant to reach steady-state was reduced to approximately 1 month.
18,42
 Furthermore, 
the residual ER that remains detectable following treatment with fulvestrant 500 mg in 
NEWEST and Trial 57
27,28
 raises the possibility that greater reductions in ER expression and 
improved efficacy could be achieved using an even higher fulvestrant dose. Fulvestrant 750 
mg, although requiring three separate 5 ml intramuscular injections, has previously been 
shown to be well tolerated, and is effective in reducing ER expression in pre-menopausal 
women.
38
 However to our knowledge, no studies using a dose higher than fulvestrant 500 mg 
for postmenopausal breast cancer have been reported, and three or more 5 mL injections per 
dose, as required by the current formulation, may present practical impediments. It should 
also be noted that if complete and irreversible elimination of ER expression could ever be 
achieved (thereby potentially making any subsequent endocrine therapy redundant), it would 
need to be established whether the total duration of control achieved by the total ER ablation 
was greater than sequential treatment with current endocrine therapies. 
Trials other than those described above have also compared dose regimens of fulvestrant in 
postmenopausal women with advanced breast cancer. The Phase II FINDER (Faslodex 
InvestigatioN of Dose evaluation in Estrogen Receptor-positive advanced breast cancer) 
studies, conducted in Japan (FINDER1) and Europe (FINDER2) investigated the efficacy and 
safety of three dose regimens of fulvestrant (fulvestrant 500 mg; fulvestrant 250 mg + LD; 
fulvestrant 250 mg) (Table 4). Although efficacy and safety were established for each of the 
fulvestrant doses in both studies, the relatively small sample sizes did not allow for any 
potential differences in efficacy to be determined between the treatment groups.
43,44
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Importantly, the biological and clinical studies analyzed here were not conducted 
concurrently, and indirect cross-trial comparisons should be interpreted with caution. 
Significant variability was observed between these studies both for absolute levels, and 
magnitude of treatment-driven change, of ER and PgR H-score and Ki67 labeling index. 
Factors that may have influenced this between-study variability include the different 
antibodies and antibody retrieval methods that were used in each of the studies, and the assay 
sensitivity, which was lower in the earlier Study 18 than NEWEST and Trial 57, where assay 
sensitivity was very high in order to reduce false-negative results.
27
 In addition, the time from 
dose to surgery or biopsy varied between the studies. However, when adjusting for between-
study variability in the analysis of tumor biomarker reduction using the second ANCOVA, 
fulvestrant demonstrated a strong dose–response relationship for reduction in ER, PgR, and 
Ki67 index. 
 
Conclusion 
Overall, the dose–response effect seen with fulvestrant in clinical studies in the advanced 
disease setting mirrors the dose-dependent reduction in tumor biomarker studies in a much 
earlier disease setting. Across all of the datasets analyzed here, a dose–response relationship 
has been demonstrated. This represents a strong demonstration of the relationship between 
the biology of tumor biomarkers and clinical efficacy which underpins rational drug 
development. 
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Table 1. Change from baseline in ER H-score.  
Treatment Back-transformed least squares mean change from baseline 
(%) 
(95% CI) 
 Study 18 NEWEST Trial 57 
initial phase 
Trial 57 
main phase 
Placebo -37.3 
(-69.5, 28.9) 
   
Tamoxifen -61.7 
(-82.5, -15.9) 
   
Fulvestrant 50 mg -67.6 
(-83.7, -35.5) 
   
Fulvestrant 125 mg -75.2 
(-87.0, -52.4) 
   
Fulvestrant 250 mg -84.0 
(-91.7, -69.1) 
-10.7 
(-30.3, 14.4) 
-21.0 
(-56.2, 42.4) 
 
Fulvestrant 500 mg  -52.9 
(-63.0, -40.1) 
 -44.6 
(-53.9, -33.4) 
Fulvestrant 250 mg plus 
anastrozole 
  -43.2 
(-68.4, 2.1) 
 
Fulvestrant 500 mg plus 
anastrozole 
   -48.9 
(-58.1, -37.6) 
Anastrozole   5.8 
(-41.0, 89.7) 
-14.7 
(-29.7, 3.5) 
CI, confidence interval; ER, estrogen receptor
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Table 2. Change from baseline in PgR H-score. 
Treatment Back-transformed least squares mean change from baseline 
(%) 
(95% CI) 
 Study 18 NEWEST Trial 57 
initial phase 
Trial 57 
main phase 
Placebo 40.3 
(-25.8, 165.4) 
   
Tamoxifen 160.1 
(27.7, 429.8) 
   
Fulvestrant 50 mg -62.7 
(-80.6, -28.6) 
   
Fulvestrant 125 mg -78.8 
(-88.4, -61.3) 
   
Fulvestrant 250 mg -86.4 
(-92.8, -74.2) 
-67.3 
(-81.0, -43.7) 
-47.5 
(-82.8, 60.3) 
 
Fulvestrant 500 mg  -91.4 
(-95.0, -85.0) 
 -63.2 
(-77.2, -40.6) 
Fulvestrant 250 mg plus 
anastrozole 
  -49.2 
(-82.9, 50.9) 
 
Fulvestrant 500 mg plus 
anastrozole 
   -58.3 
(-75.5, -29.0) 
Anastrozole   -65.9 
(-88.8, 4.0) 
-59.2 
(-75.0, -33.6) 
CI, confidence interval; PgR, progesterone receptor. 
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Table 3. Change from baseline in Ki67 labeling index. 
Treatment Back-transformed least squares mean change from baseline 
(%) 
(95% CI) 
 Study 18 NEWEST Trial 57 
initial phase 
Trial 57 
main phase 
Placebo 3.7 
(-18.0, 31.1) 
   
Tamoxifen 35.8 
(-51.3, -15.5) 
   
Fulvestrant 50 mg -23.3 
(-40.6, -0.9) 
   
Fulvestrant 125 mg -46.1 
(-58.6, -29.7) 
   
Fulvestrant 250 mg -46.5 
(-58.1, -31.6) 
-45.5 
(-58.5, -28.2) 
-79.0 
(-90.4, -53.7) 
 
Fulvestrant 500 mg  -81.2 
(-85.8, -75.0) 
 -74.4 
(-81.5, -64.5) 
Fulvestrant 250 mg plus 
anastrozole 
  -91.1 
(-96.0, -80.2) 
 
Fulvestrant 500 mg plus 
anastrozole 
   -83.4 
(-88.5, -76.0) 
Anastrozole   -84.4 
(-92.9, -65.6) 
-85.0 
(-89.1, -79.4) 
CI, confidence interval. 
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Table 4. PFS in fulvestrant monotherapy trials for advanced breast cancer. 
  PFS (months) 
 Study design Fulvestrant 
250 mg 
Fulvestrant 
250 mg + 
LD 
Fulvestrant 
500 mg 
Tamoxifen 
20 mg/day 
Anastrozole 
1 mg/day 
Exemestane 
25 mg/day 
Second-line studies        
 Study 20
a
 Phase III, randomized, open-label, 
parallel-group, multicenter study: 
fulvestrant 250 mg, n=222; 
anastrozole, n=229 
23
. 
5.5    5.1  
 Study 21
a
 Phase III, randomized, double-blind, 
parallel-group, double-dummy, 
multicenter study: fulvestrant 
250 mg, n=206; anastrozole, n=194 
24
. 
5.4    3.4  
 EFECT Phase III, randomized, double-blind, 
double-dummy, multicenter study: 
fulvestrant 250 mg + LD, n=351; 
exemestane, n=342 
18
. 
 3.7    3.7 
 FINDER1 Phase II, randomized, double-blind, 
parallel-group, multicenter study: 
fulvestrant 500 mg, n=47; fulvestrant 
250 mg + LD, n=51; fulvestrant 
250 mg, n=45 
43
. 
6.0 7.5 6.0    
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 FINDER2 Phase II, randomized, double-blind, 
parallel-group, multicenter study: 
fulvestrant 500 mg, n=46; fulvestrant 
250 mg + LD, n=51; fulvestrant 
250 mg, n=47 
44
 
3.1 6.1 6.0    
 CONFIRM Phase III, randomized, double-blind, 
parallel-group, multicenter study: 
fulvestrant 500 mg, n=362; 
fulvestrant 250 mg, n=374 
25
. 
5.5  6.5    
First-line studies        
 Trial 25 Phase III, randomized, double-blind, 
parallel-group, double-dummy, 
multicenter study: fulvestrant 
250 mg, n=313; tamoxifen, n=274 
30
. 
6.8   8.3   
 FIRST
b
 Phase II, randomized, open-label, 
parallel-group, multicenter study: 
fulvestrant 500 mg, n=102; 
anastrozole, n=103 
14
. 
  23.4  13.1  
a
Studies 0020 and 0021 initially included a fulvestrant 125 mg treatment group that was withdrawn due to lack of clinical activity. 
b
Data from the FIRST follow-up analysis.  
Fulvestrant 250 mg: 250 mg Days 0 and 28, 250 mg/month thereafter; fulvestrant 250 mg + LD: 500 mg Day 0, 250 mg Days 14 and 28, 
250 mg/month thereafter; fulvestrant 500 mg: 500 mg Days 0, 14 and 28, 500 mg/month thereafter.  
LD, loading dose; PFS, progression-free survival
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Figure legends 
Figure 1. Change from baseline in ER expression.  
Figure 2. Change from baseline in PgR expression. 
 Figure 3. Change from baseline in Ki67 labeling index. 
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Figure 1. Change from baseline in ER expression.  
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Figure 2. Change from baseline in PgR expression. 
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Figure 3. Change from baseline in Ki67 labeling index. 
 
